Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Sells Boulder Facility, Lays off 60 to Trim Costs Amid Mounting Q3 Losses

NEW YORK, Nov. 15 (GenomeWeb News) - Transgenomic has sold its oligonucleotide-manufacturing facility and laid off 60 staffers worldwide as the struggling company takes steps to trim expenses and save cash, the company disclosed today.

 

Transgenomic announced the belt-tightening moves as part of its third-quarter financial report, in which a mild up-tick in revenue amid widening losses and slightly more than $1 million in the bank painted a bleak near-term picture for the Omaha, Neb.-based company.

 

Transgenomic said Eyetech Pharmaceuticals paid $3 million for "substantially all" of the assets of its Boulder, Colo.-based synthetic oligo shop. Eyetech also assumed equipment and "other operating leases" associated with the Boulder facility.

 

Eyetech will also retain "essentially all" of the staffers employed at the Boulder facility, Transgenomic said in a statement. The company stressed that the sale will not affect its manufacturing facility in Glasgow, Scotland.

 

Additionally, Transgenomic will lay off around 60 employees worldwide, and close two US-based research and development facilities linked to the firm's synthetic nucleic acid business, and two European field offices.

 

The divestiture and lay-offs are expected to save Transgenomic between $10 million and $12 million per year.

 

Revenue for the three months ended Sept. 30 inched up to $8.2 million from $7.5 million year over year.

 

Net losses ballooned to $8.4 million, or $.29 per share, from $6.1 million, or $.25 per share, in the year-ago quarter.

 

R&D spending decreased to $1.7 million for the third quarter, from $2.4 million in the comparable period of 2003.

 

Transgenomic held cash and cash equivalents of $1.1 million as of Sept. 30.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.